

First dose of BNT162b2 mRNA vaccine in a Health Care Worker cohort is associated with reduced symptomatic and asymptomatic SARS-CoV-2 infection

Patrick J Lillie – Infection Research Group, Dept of Infection, Hull Teaching Hospitals, Hull, United Kingdom

Paul O'Brien – Dept of Pharmacy, Hull Teaching Hospitals, Hull, United Kingdom

Michelle Lawtie – Staff testing service, Hull Teaching Hospitals, Hull, United Kingdom

Steve Jessop – Lead nurse vaccine roll out team, Hull Teaching Hospitals, Hull, United Kingdom

Nicholas JW Easom – Infection Research Group, Dept of Infection, Hull Teaching Hospitals, Hull, United Kingdom

Russell Patmore – Dept of Haematology, Hull Teaching Hospitals, Hull, United Kingdom

Corresponding author – Patrick Lillie, – Dept of Infection, Castle Hill Hospital Hull Teaching Hospitals, Hull, HU16 5JQ United Kingdom, email – patrick.lillie@hey.nhs.uk

Abstract

Over the first 2 months of 2021 vaccination coverage of staff at Hull Teaching Hospitals with BNT162b2 increased from 8.3% to 82.5%, and was associated with a significant reduction in symptomatic and asymptomatic SARS-CoV-2 cases. The proportion of positive lateral flow tests from asymptomatic screening was maintained over this period.

Keywords: SARS-CoV-2; COVID-19: Vaccination; BNT162b2; Lateral Flow Test

Accepted Manuscript

Introduction

The roll-out of vaccination against SARS-CoV-2 in the United Kingdom has included health care workers as a priority group. The efficacy of currently licensed vaccines against symptomatic disease is well documented from clinical trials^{1,2}, however there are fewer data with regard to asymptomatic shedding of virus, or the changing pattern of symptoms of those infected as vaccination programs progress. Hull University Teaching Hospitals has used the Pfizer-BioNtech vaccine (BNT 162b2) for staff vaccination, and has been recording testing for SARS-CoV-2 by both Nucleic Acid Amplification Tests (NAAT) for all symptomatic staff and specific screening, together with routine (asymptomatic) Lateral Flow Device (LFD) testing of all clinical staff. Here we present the effect of the vaccine roll out on staff PCR and LFD positivity across symptomatic and asymptomatic groups.

Methods

Vaccination with BNT 162b2 began in staff on the 9th December 2020, with a planned acceleration in staff vaccination from the 28th December 2020 (figure 1). Vaccination was carried out as per guidelines from Public Health England & the Department of Health³. As per guidance from the Joint Committee on Vaccination and Immunisation (JCVI)³ initial doses have been administered with the booster dose planned for 10 – 12 weeks post first vaccination.

Since April 2020, symptomatic staff testing for possible COVID-19 disease has been performed. In addition to testing being triggered by classical symptoms of COVID-19 as per PHE guidance⁴ (fever, cough, shortness of breath, loss of smell / taste), we have tested healthcare workers (HCWs) with milder atypical symptoms (nasal symptoms, sore throat, diarrhoea, headache, myalgia / arthralgia) as well as targeted screening during outbreaks and routine screening of staff working on the stem cell transplant unit (116 staff members). Staff contact the hospital testing team and attend within 24 hours for a combined nose and throat swab, which is processed internally by the virology

department. A variety of molecular assays are used, with the majority of routine tests being performed using the Panther Fusion (Hologic) assay. Clinical staff in all areas have been performing and electronically self reporting their own LFD tests (Innova) as twice weekly asymptomatic testing since 27th November 2020. Data on symptomatic / asymptomatic / LFD testing are presented from the week beginning 4th Jan 2021. We are unable to directly link vaccination status to NAAT or LFD testing amongst staff. All data were collected during routine working practice and no ethical approval was deemed necessary, with the COVID-19 steering group for the trust approving data collection and usage. Statistical testing was performed using GraphPad Prism version 6.

Results

By 4th January 2021 827 (8.3%) staff had received their first dose of BNT 162 b2, increasing to 8243 (82.5%) by the end of the week 22nd February. NAAT-proven cases of SARS-CoV-2 amongst staff reduced from 120 cases in the week 4th Jan, to 10 cases in the week 22nd Feb (Figure 1). There was a significant negative correlation between cumulative vaccination and PCR positive cases (Pearsons R = -0.9061, p=0.0019), along with a marked correlation between symptomatic PCR testing rates and vaccine coverage (Pearsons R = -0.8972, p=0.0025). The number of staff self isolating as positive for SARS-CoV-2 on the 11th January was 325, dropping to 91 on the 23rd February (72% decrease), with a 68% reduction in staff isolating due to a positive household contact (100 decreasing to 32), with a smaller decrease in the same time period in non COVID-19 absence from work (413 decreasing to 328, a 20.58% decrease). Figures 2a and 2b show the relationship between symptomatic / asymptomatic PCR positive cases and date as a marker of vaccine coverage, with a significant correlation between cumulative vaccination and reduction in all categories, p<0.005 for symptomatic and asymptomatic. . Lateral flow testing rates declined over the period from 4269 tests week of 4th Jan to 1755 tests recorded in the week of 22nd Feb, however the proportion of LFD tests reading positive was maintained over this time (R=0.7012, p=0.0527) with between 1.3% and

0.45% being positive. Amongst vaccinated staff 13 positive LFD tests were confirmed by NAAT testing, all within 14 days of their vaccination. Figure 1b shows the rate of SARS-CoV-2 positive testing in Kingston upon Hull (data obtained from PHE website) during the same time period, showing an initial rate of 332.6 / 100,000 on 9th Jan 2021 to 144.4 /100,000 on the 19th Feb 2021 and plateauing from that point. Very few cases of lineage B1.1.7 were present during this period on available whole genome sequencing data, and no other variants of concern were reported.

Discussion

Health care workers are at high risk of being exposed to SARS-CoV-2⁵ and vaccination of this group is a priority. Together with recent data from the SIREN study across UK health care⁶, these data highlight the high level of efficacy of the BNT162b2 vaccine against both symptomatic and asymptomatic infection. We have found that this effect is noted in atypical as well as typical symptoms of COVID-19, hopefully allowing current testing and screening programs to maintain criteria. .

Asymptomatic testing with LFDs has decreased over time, but the proportion of positive tests has remained relatively static, suggesting that sensitivity may be maintained post-vaccination. As the testing by LFD is for routine asymptomatic screening, it is unlikely that the reduction in testing reporting is a direct consequence of the vaccination program, but may reflect both “testing fatigue” or perceived protection from the vaccination. Under reporting, particularly of negative tests is a possible source of bias in this data. In health care settings where positive LFD tests can be confirmed by NAAT testing, these tests may retain utility in a vaccinated group.

Limitations of our data include only short term effectiveness being ascertained, it is an ecological study as opposed to any controlled data and it is data from a single centre in the context of a national vaccine roll out program therefore applicability to other settings is likely to be limited.

In conclusion single dose BNT162b2 has been associated with a significant decrease in positive PCR for SARS-CoV-2 in both symptomatic and asymptomatic HCW's, with the most dramatic effect on symptomatic illness. Utility of LFD testing positive test rate seems to be unaffected by the vaccine roll out and may continue to provide a useful screening tool in vaccinated cohorts.

Conflict of interest; Dr Easom has received lateral flow test kits from Mologic Ltd for an unrelated project. All other authors have no conflicts of interest.

Accepted Manuscript

References

1. Pollack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020; **383**: 2603-2615
2. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK. *Lancet* 2021; **397**: 99-111
3. Immunisation against infectious disease, The Green Book.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961287/Greenbook_chapter_14a_v7_12Feb2021.pdf Accessed 7th March 2021
4. COVID-19: investigation and initial clinical management of possible cases.
<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection> Updated December 14th 2020, accessed 8th March 2021
5. Houlihan CF, Vora N, Byrne T, et al. Pandemic Peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. *Lancet* 2020 ; **396**: e6-e7
6. Hall VJ, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). Available at SSRN: <https://ssrn.com/abstract=3790399>

FIGURE LEGENDS

Figure 1a– Vaccination coverage and PCR positive test numbers

Figure 1 b – Positive PCR tests / 1000,000 in Kingston upon Hull during study period

Figure 2 A – PCR positive cases by symptom type, B, all symptomatic vs asymptomatic PCR cases

Accepted Manuscript

Figure 1




Figure 2

